Clinical trial
A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06650808 IN PATIENTS WITH ADVANCED SOLID TUMORS
NCT02129205 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06650808 IN PATIENTS WITH ADVANCED SOLID TUMORS
- Lead sponsor
- Pfizer
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- June 30, 2014
- Completion date
- July 31, 2017
- Enrollment
- 40 (actual)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.
breast cancer, neoplasms